TABLE 1

Summary of the effect of treatment on pre-bronchodilator forced expiratory volume in 1 s (FEV1), asthma exacerbations and mortality

Study [ref.]Subjects nDuration weeksAsthma severity#Treatment groupChange from baseline in pre-bronchodilator FEV1 mLExacerbationsMortality %+
OverallED and hospitalisation
Busse et al. [79]36 01026ModerateICSNot reported11.7%0.60%0
ICS/LABANot reported9.8%0.66%0
DREAM [80]61652SeverePlacebo602.400.430
Mepolizumab115–1401.15–1.460.17–0.251
MENSA [81]57632SeverePlacebo861.740.201
Mepolizumab183–1860.83–0.930.08–0.140
MUSCA [82]55124SeverePlacebo561.210.100
Mepolizumab1760.510.030
CALIMA [83]130656SeverePlacebo215§0.93§0.04§0
Benralizumab330–340§0.60–0.66§0.04–0.05§0
SCIROCCO [84]120548SeverePlacebo239§1.33§0.18§0
Benralizumab345–398§0.65–0.73§0.06–0.11§0
Castro et al. [85]95352SeverePlacebo1201.810.120
Reslizumab2200.840.0770
QUEST [86]190252Moderate-to-severePlacebo180–210ƒ0.87–0.970.0650
Dupilumab320–340ƒ0.46–0.520.0350

Ranges indicate results with different doses/routes of administration. ED: emergency department; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist. #: asthma severity based on treatment requirements and prior asthma exacerbation rates; : events are expressed as episodes per patient per year, unless otherwise specified; +: rounded to 0 decimal places; §: data are for the subgroup with severe asthma and eosinophils ≥300 cells·µL−1 (n=728 in CALIMA and n=809 in SCIROCCO); ƒ: change from baseline at week 12 (all other FEV1 data presented as change from baseline at the final study visit).